Your browser doesn't support javascript.
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?
J Gastrointest Oncol ; 5(3): 166-77, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24982765
The role of adjuvant chemoradiation (CRT) for pancreas cancer remains unclear. A handful of randomized trials conducted decades of ago ignited a debate that continues today about whether CRT improves survival after surgery. The many flaws in these trials are well described in the literature, which include the use of antiquated radiation delivery techniques and suboptimal doses. Recent prospective randomized data is lacking, and we eagerly await the results the ongoing Radiation Therapy Oncology Group (RTOG) 0848 trial that is evaluating the utility of high quality adjuvant CRT in resected pancreas cancer patients. Until the results of RTOG 0848 are available we should look to other studies from the modern era to guide adjuvant treatment recommendations. Here we review the current state of the art for adjuvant pancreas CRT with respect to patient selection, radiation techniques, radiation dose, and integration with novel systemic agents.





Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Ensayo clínico controlado Idioma: Inglés Revista: J Gastrointest Oncol Año: 2014 Tipo del documento: Artículo País de afiliación: Estados Unidos